Blood tests could reveal who benefits from immunotherapy
NCT ID NCT05091190
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how well immunotherapy works in people with advanced lung or head and neck cancers. Researchers will take blood samples before and after treatment to measure how the body clears the drug and how tumor cells in the blood change. The goal is to find markers that predict who will respond best to immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immunotherapy
- What this could lead to
- If successful, this could help doctors predict which patients will benefit from immunotherapy, leading to more personalized cancer treatment.
- What could go wrong
- This is an observational study with only 75 participants, so results may not apply to all patients. It measures biomarkers, not direct treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Croix Rousse Hospital
Lyon, France
-
Lyon Sud Hospital
Pierre-Bénite, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple test predict immunotherapy success in head and neck cancer?
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- New combo therapy shows promise for incurable head and neck cancer
- New hope for lung cancer: experimental drug combo enters final testing phase
- New drug cocktail shows promise for tough head and neck cancers
- Ultrasound boosts cancer drug in tiny trial